Department of Urology, Royal Hallamshire Hospital, Sheffield, UK.
Eur Urol. 2013 Dec;64(6):965-73. doi: 10.1016/j.eururo.2013.07.038. Epub 2013 Aug 3.
Female urethral stricture (FUS) is a rare and challenging clinical entity. Several new surgical techniques have been described for the treatment of FUS, although with the limited number of reports, there is no consensus on best management.
We evaluated the evidence for surgical interventions reported for treating FUS.
We performed a systematic review of the PubMed and Scopus databases, classifying the results by surgical technique and type of graft in the case of graft augmentation urethroplasty.
A total of 221 patients have been reported on with outcome measures after intervention for FUS. The mean age of women was 51.8 yr of age (range: 22-91). All studies were retrospective case series. There was no consistent definition of FUS nor unified diagnostic criteria. Most studies used a combination of diagnostic tests. Where aetiology was defined, idiopathic and iatrogenic stricture were the two most common causes. Ninety-eight patients underwent prior intervention for FUS, mostly urethral dilatation or urethrotomy. Success was defined as the lack of need for further intervention. Urethral dilatation, assessed in 107 patients, had a mean success rate of 47% at a mean follow-up of 43 mo. Fifty-eight patients had vaginal or labial flap augmentation, with a mean success rate of 91% at 32.1 mo of mean follow-up. Vaginal or labial graft augmentation had a mean success rate of 80% in 25 patients at a mean follow-up of 22 mo. Oral mucosal augmentation, performed in 32 patients, had a mean success rate of 94% at 15 mo of mean follow-up. No instances of de novo stress incontinence were reported.
The techniques of urethroplasty all have a higher mean success rate (80-94%) than urethral dilatation (<50%), although with shorter mean follow-up. Urethroplasty in experienced hands appears to be a feasible option in women who have failed urethral dilatation, although there is a lack of high-level evidence to recommend one technique over another.
女性尿道狭窄(FUS)是一种罕见且具有挑战性的临床病症。已经描述了几种新的手术技术来治疗 FUS,尽管由于报告数量有限,对于最佳治疗方法尚未达成共识。
我们评估了用于治疗 FUS 的手术干预措施的证据。
我们对 PubMed 和 Scopus 数据库进行了系统评价,根据手术技术和移植物类型对结果进行分类,在移植物增强尿道成形术中则是根据移植物类型进行分类。
总共报道了 221 例接受 FUS 干预后的患者,评估了他们的结果。女性的平均年龄为 51.8 岁(范围:22-91 岁)。所有研究均为回顾性病例系列研究。对于 FUS 没有统一的定义,也没有统一的诊断标准。大多数研究都使用了一系列诊断测试。在定义病因的研究中,特发性和医源性狭窄是最常见的两个原因。98 例患者因 FUS 接受了先前的介入治疗,主要是尿道扩张或尿道切开术。成功的定义是无需进一步介入。在 107 例接受尿道扩张评估的患者中,平均成功率为 47%,平均随访时间为 43 个月。58 例患者接受了阴道或阴唇皮瓣增强术,平均随访 32.1 个月,平均成功率为 91%。25 例接受阴道或阴唇移植物增强术的患者平均随访 22 个月,成功率为 80%。32 例接受口腔黏膜增强术的患者平均随访 15 个月,成功率为 94%。没有新发生压力性尿失禁的报告。
与尿道扩张术(<50%)相比,尿道成形术的所有技术都具有更高的平均成功率(80-94%),尽管平均随访时间较短。在有经验的医生手中,对于已经失败的尿道扩张术的女性患者,尿道成形术似乎是一种可行的选择,尽管缺乏推荐一种技术优于另一种技术的高级别证据。